We are live on
!
Find out more
EAM
Exome Asset Management Portfolio holdings
AUM
$193M
1-Year Est. Return
208.51%
This Fund
S&P 500
This Quarter
Est. Return
+14.64%
1 Year Est. Return
+208.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$193M
AUM Growth
-$15.8M
(-7.6%)
Cap. Flow
-$20.2M
Cap. Flow
% of AUM
-10.45%
Top 10 Holdings %
Top 10 Hldgs %
42.42%
Holding
83
New
23
Increased
5
Reduced
24
Closed
27
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Insmed
INSM
|
+$4.1M |
| 2 |
Rhythm Pharmaceuticals
RYTM
|
+$3.95M |
| 3 |
MAZE
Maze Therapeutics
MAZE
|
+$3.91M |
| 4 |
Boston Scientific
BSX
|
+$3.87M |
| 5 |
MoonLake Immunotherapeutics
MLTX
|
+$3.57M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Wave Life Sciences
WVE
|
+$5.49M |
| 2 |
AstraZeneca
AZN
|
+$5.26M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
+$4.5M |
| 4 |
Immunovant
IMVT
|
+$4.03M |
| 5 |
Praxis Precision Medicines
PRAX
|
+$3.91M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Establishment Labs
ESTA
$2.82B
| $744K | 0.38% |
13,100
| – | – |
|
52
PUT
Travere Therapeutics
TVTX
$5.26B
| $594K | 0.31% |
20,000
-54,700
| -73% | -$1.64M |
|
53
Lipocine
LPCN
$18.1M
| $486K | 0.25% |
+60,861
| New | +$530K |
|
54
Arbutus Biopharma
ABUS
$893M
| $340K | 0.18% |
75,484
| – | – |
|
|
55
PUT
Wave Life Sciences
WVE
$1.11B
| $218K | 0.11% |
+30,000
| New | +$391K |
|
56
CALL
Compass Therapeutics
CMPX
$378M
| $133K | 0.07% |
+25,100
| New | +$145K |
|
57
CALL
Aldeyra Therapeutics
ALDX
$106M
| – | – |
-100,000
| Closed | -$518K |
|
|
58
AstraZeneca
AZN
$263B
| – | – |
-14,181
| Closed | -$5.26M |
|
|
BLTE
59
Belite Bio
BLTE
$6.46B
| – | – |
-14,328
| Closed | -$2.29M |
|
60
Celcuity
CELC
$4.47B
| – | – |
-34,289
| Closed | -$3.42M |
|
61
DexCom
DXCM
$28.8B
| – | – |
-50,147
| Closed | -$3.33M |
|
62
Edgewise Therapeutics
EWTX
$4.26B
| – | – |
-100,046
| Closed | -$2.48M |
|
63
Fulcrum Therapeutics
FULC
$245M
| – | – |
-92,055
| Closed | -$1.04M |
|
64
Gossamer Bio
GOSS
$75.7M
| – | – |
-451,699
| Closed | -$1.4M |
|
65
Inhibikase Therapeutics
IKT
$350M
| – | – |
-600,000
| Closed | -$1.23M |
|
66
Immunocore
IMCR
$1.75B
| – | – |
-76,750
| Closed | -$2.66M |
|
|
67
Immunovant
IMVT
$8.12B
| – | – |
-158,622
| Closed | -$4.03M |
|
68
IQVIA
IQV
$33.7B
| – | – |
-5,378
| Closed | -$1.21M |
|
69
Disc Medicine
IRON
$2.89B
| – | – |
-46,743
| Closed | -$3.71M |
|
|
70
PUT
Disc Medicine
IRON
$2.89B
| – | – |
-16,000
| Closed | -$1.27M |
|
71
Ironwood Pharmaceuticals
IRWD
$644M
| – | – |
-648,532
| Closed | -$2.19M |
|
|
72
Jazz Pharmaceuticals
JAZZ
$16B
| – | – |
-26,494
| Closed | -$4.5M |
|
73
Karyopharm Therapeutics
KPTI
$178M
| – | – |
-295,541
| Closed | -$2.18M |
|
74
PUT
Precigen
PGEN
$1.96B
| – | – |
-100,000
| Closed | -$418K |
|
75
CALL
Ultragenyx Pharmaceutical
RARE
$2.82B
| – | – |
-35,200
| Closed | -$810K |
|
Similar funds
WWC
JHA
TDWM
MUAMU
DF
BW
SCM
CWRP
Exome Asset Management's Q1 2026 Portfolio in Review
As of Q1 2026, Exome Asset Management held 83 positions worth $193M, down 7.6% from $209M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Exome Asset Management withdrew a net $20.2M in Q1 2026, closing 27 positions and reducing 24 holdings. Its most notable exit was Wave Life Sciences, an estimated $5.49M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 97% a quarter earlier.
Against the trend, Exome Asset Management opened a new position in Insmed worth $4.36M.
- Exome Asset Management's largest Q1 2026 buy was Insmed: 26,651 shares worth $4.36M.
- Exome Asset Management added most to UnitedHealth in Q1 2026, an estimated $2.09M increase.
- Exome Asset Management's biggest Q1 2026 reduction was Praxis Precision Medicines, cutting an estimated $3.91M.
- Exome Asset Management fully exited Wave Life Sciences in Q1 2026, selling an estimated $5.49M.
- Exome Asset Management's ten largest holdings make up 42% of its $193M portfolio in Q1 2026.
- Exome Asset Management opened 23 new positions and closed 27 in Q1 2026.
- Exome Asset Management's portfolio value fell 7.6% quarter-over-quarter to $193M.
Based on Exome Asset Management's 13F filing for Q1 2026, filed 15 May 2026.